I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating on Clene with a $31 price target, citing clinical and regulatory progress for its ALS asset CNM-Au8. New biomarker data linking neurofilament light chain reduction to survival outcomes addresses prior FDA feedback, strengthening the case for an NDA submission in Q4 2026 and potential accelerated approval.
Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Clene. The associated price target remains the same with $31.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Joseph Pantginis has given his Buy rating due to a combination of factors tied to both clinical and regulatory progress for Clene’s lead asset, CNM-Au8, in ALS. He highlights newly reported biomarker data showing that reductions or stabilization in neurofilament light chain (NfL) are closely associated with longer survival and better functional outcomes, reinforcing NfL as a mechanistic and regulatory anchor for the program.
Pantginis also notes that these data appear to directly address prior FDA feedback by clearly linking the magnitude of NfL reduction to clinical benefit, thereby strengthening the company’s planned NDA submission in 4Q26 and its case for potential accelerated approval. He emphasizes that the NDA will be supported by a broad body of evidence from multiple trials and long-term datasets, which in his view “checks all the boxes” for a robust regulatory package and underpins his unchanged $31 price target and Buy recommendation.
Pantginis covers the Healthcare sector, focusing on stocks such as Kura Oncology, Cytokinetics, and Rigel. According to TipRanks, Pantginis has an average return of 21.5% and a 52.34% success rate on recommended stocks.